The history of proton therapy in pediatric oncology is, at its core, a story about what we owe children who survive cancer. For decades, the dominant concern in treating malignant brain tumors in children was survival — and justifiably so, given that many pediatric central nervous system tumors, including medulloblastoma and ependymoma, are aggressive diseases that demanded aggressive treatment. Radiation therapy was essential to that treatment, and it worked. Survival rates improved significantly over the second half of the twentieth century. But as those survivors grew up, a different kind of reckoning began. Cognitive impairment, growth hormone deficiencies, hearing loss, cardiovascular damage, and elevated rates of secondary malignancies emerged as the long-term price of delivering photon radiation to the developing brain. The question that followed was whether there was a way to preserve the tumor control that radiation provided while protecting the healthy tissue that would shape a survivor’s entire adult life.

Proton therapy offered a biophysically distinct answer. Unlike conventional X-ray radiation, which deposits dose along its entire path through the body and beyond the tumor, protons deposit the vast majority of their energy at a precise depth — a phenomenon known as the Bragg peak — then stop. This physical property allows radiation oncologists to deliver a therapeutic dose to a tumor while substantially reducing the radiation received by surrounding healthy brain tissue, the brainstem, the cochlea, the hypothalamus, and the spinal cord. In pediatric brain tumor treatment, where these structures are actively developing and uniquely vulnerable to radiation injury, the dosimetric advantages of proton therapy translate into measurable real-world outcomes. Multiple prospective and retrospective studies have demonstrated that children with medulloblastoma treated with proton craniospinal irradiation show significantly better neurocognitive outcomes — including preservation of IQ, memory, and processing speed — compared to historical cohorts treated with photon radiation.

The late-effects data from pediatric proton therapy has accumulated to a point where it is now influencing how radiation oncologists approach adult brain tumor treatment, particularly for diagnoses where long-term survival is increasingly common. Adults with low-grade gliomas — tumors that may be managed over years or decades with watchful waiting, surgery, and radiation — face a lifetime risk of radiation-related cognitive effects that is now being taken far more seriously than it was a generation ago. Glioma survivors in their thirties, forties, and fifties who are expected to live for many years with their disease have a great deal to lose from radiation-induced cognitive decline. The pediatric literature provides the most rigorous available evidence that proton therapy can preserve cognitive function in irradiated brain tissue, and that evidence is being applied — carefully, and with appropriate humility about the differences between developing and mature brains — to adult treatment decisions.

At major proton centers, including the Oklahoma Proton Center, the treatment of adult brain tumors with proton therapy has expanded significantly as the clinical rationale has strengthened. Meningiomas, pituitary tumors, craniopharyngiomas, and skull base tumors are among the adult diagnoses where proton therapy is increasingly supported by clinical data and endorsed in guidelines. For gliomas, the evidence base continues to develop. Several ongoing clinical trials are directly comparing photon and proton radiation in adult glioma patients, with cognitive function and quality of life as primary endpoints alongside tumor control. The results of those trials will be meaningful — but even in their absence, many radiation oncologists are now incorporating proton therapy into adult brain tumor care for patients where organs at risk and expected survival make the dosimetric advantages clinically significant.

For patients and families navigating a brain tumor diagnosis, understanding proton therapy as an option requires a candid conversation with a radiation oncologist who has specific expertise in both the disease and the technology. Not every brain tumor diagnosis benefits equally from proton therapy, and access to proton centers, while expanding, remains geographically uneven. Insurance coverage has improved substantially as the clinical evidence has matured, but prior authorization processes can be complex and require advocacy. The pediatric experience has given us something invaluable: proof that the brain can be treated, and protected, simultaneously. That proof is now translating into better care for adults — not just for the tumor, but for the life that follows treatment.